Full history for every metric is available with a Kvantra account
CombiMatrix Corporation (CBMX)
Key financial summary
Financials in USD| 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 5 | 5 | 6 | 8 | 10 | 13 | 16 |
| Operating profit | $m | -4 | -2 | |||||
| Net profit | $m | -8 | -10 | -4 | -9 | -7 | -4 | -2 |
| EPS reported | $ | -2.34 | -0.84 | |||||
| Operating cashflow per share | $ | - | -2.21 | |||||
| Capex per share | $ | - | 0.09 | |||||
| FCF per share | $ | - | -2.29 | |||||
| Free cash flow | $m | -4 | -2 | |||||
| Net debt | $m | -4 | -5 | |||||
| Book value equity | $m | 6 | 5 | |||||
| Book value per share | $ | 3.67 | 1.84 | |||||
| Number of shares | m | 1.77 | 2.87 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 0.72 | 1.70 | |||||
| P/S LTM | x | 0.36 | 0.00 | |||||
| P/FCF LTM | x | -1.15 | 0.00 | |||||
| EV/EBITDA LTM | x | -0.54 | 0.66 | |||||
| EV/Sales LTM | x | - | -0.20 | |||||
| Earnings Yield LTM | % | - | -37.46% | |||||
| FCF Yield | % | -86.59% | - | |||||
| Quality | ||||||||
| ROE | % | - | -67.04% | |||||
| ROIC | % | - | -60.29% | |||||
| Operating margin | % | - | -31.81% | |||||
| Gross margin | % | - | 55.03% | |||||
| FCF/Sales | % | - | -31.53% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | +27.57% | +29.73% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | - | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | - | 0.00% | |||||
| FCF/Debt | x | -27.05 | -8.50 | |||||
| Net Debt/EBITDA | x | - | 0.66 | |||||
| EBIT/Net interest | x | - | 0.00 | |||||
| Net debt/market cap | % | -76.34% | - | |||||
| Net debt/Equity | x | -0.55 | -0.87 | |||||
| Gross debt/equity | x | 0.02 | 0.04 | |||||
Company overview
CombiMatrix Corporation operates as a biotechnology firm. Its primary focus is on developing innovative technology to manufacture DNA microarrays. These specialized arrays are instrumental in identifying and understanding the roles of genes, their mutations, and various proteins. The applications for this technology are extensive, reaching into fields such as genomics, proteomics, biosensor creation, pharmaceutical research and development (including drug discovery), medical diagnostics, combinatorial chemistry, material science, and nanotechnology.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
CombiMatrix Corporation (CBMX)
CombiMatrix Corporation operates as a biotechnology firm. Its primary focus is on developing innovative technology to manufacture DNA microarrays. These specialized arrays are instrumental in identifying and understanding the roles of genes, their mutations, and various proteins. The applications for this technology are extensive, reaching into fields such as genomics, proteomics, biosensor creation, pharmaceutical research and development (including drug discovery), medical diagnostics, combinatorial chemistry, material science, and nanotechnology.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free